Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Cash from Operations (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Cash from Operations for 9 consecutive years, with 7151000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Operations fell 48.21% to 7151000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 35400000.0, a 12.7% decrease, with the full-year FY2024 number at 35400000.0, down 12.7% from a year prior.
  • Cash from Operations was 7151000.0 for Q4 2024 at SELLAS Life Sciences, up from 7806000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3424000.0 in Q4 2020 to a low of 12127000.0 in Q1 2023.
  • A 5-year average of 6352850.0 and a median of 6354500.0 in 2020 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 181.99% in 2020, then tumbled 245.33% in 2021.
  • SELLAS Life Sciences' Cash from Operations stood at 3424000.0 in 2020, then crashed by 245.33% to 4976000.0 in 2021, then fell by 3.54% to 5152000.0 in 2022, then rose by 6.35% to 4825000.0 in 2023, then tumbled by 48.21% to 7151000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLS's Cash from Operations are 7151000.0 (Q4 2024), 7806000.0 (Q3 2024), and 9682000.0 (Q2 2024).